VPC03090 is an orally active prodrug of S1P1 / 3 antagonist. VPC03090 is phosphorylated by sphingosine kinase 2 ( SK2 ) to form its active form VPC03090-P. VPC03090 reduces tumor volume in mouse breast cancer models. VPC03090 can be used in research related to breast cancer .
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > LPL Receptor | Products > Signaling Pathways > SphK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.